Literature DB >> 18662272

Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis.

Yasuaki Takeyama1, Yuko Uehara, Shinjiro Inomata, Daisuke Morihara, Shinya Nishizawa, Shu-ichi Ueda, Teruo Matsumoto, Takashi Tanaka, Akira Anan, Hirokatsu Nishimura, Makoto Irie, Kaoru Iwata, Satoshi Shakado, Tetsuro Sohda, Shotaro Sakisaka.   

Abstract

BACKGROUND/AIMS: The hepatic expression of bile acid transporters is altered in experimental cholestasis and it is unclear whether regulation exists in human cholestatic diseases. We investigated the expression of genes involved in bile acid detoxification, basolateral export and nuclear factor regulation in untreated primary biliary cirrhosis (PBC).
METHODS: Liver tissues were obtained from patients with early-stage and late-stage PBC. The hepatic expression levels of messenger RNAs were determined by the real-time reverse transcription polymerase chain reaction.
RESULTS: The hepatic expression of multidrug-resistance protein 4 messenger RNA was significantly upregulated in early-stage and late-stage PBC patients compared with controls. The hepatic expression of multidrug-resistance protein 2 and multidrug-resistance protein 3 messenger RNAs was significantly elevated only in early-stage PBC patients. The hepatic expression levels of farnesoid X receptor, fetoprotein transcription factor and constitutive androstane receptor mRNAs were correlated with those of multidrug-resistance protein 2, multidrug-resistance protein 3 and multidrug-resistance protein 4 respectively.
CONCLUSIONS: The hepatic expression of multidrug-resistance protein 4 was enhanced in patients with untreated PBC at all stages. However, the hepatic expression of multidrug-resistance protein 2 and multidrug-resistance protein 3 was enhanced only in early-stage patients. The lack of upregulation of these proteins might contribute to the progression of PBC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18662272     DOI: 10.1111/j.1478-3231.2008.01846.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

1.  Increased hepatic ABCA1 transporter is associated with hypercholesterolemia in a cholestatic rat model and primary biliary cholangitis patients.

Authors:  Yasuaki Takeyama; Yuko Uehara; Akira Anan; Daisuke Morihara; Keiji Yokoyama; Kazuhide Takata; Takashi Tanaka; Makoto Irie; Kaoru Iwata; Satoshi Shakado; Tetsuro Sohda; Shotaro Sakisaka
Journal:  Med Mol Morphol       Date:  2017-06-28       Impact factor: 2.309

Review 2.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

4.  Sustained upregulation of sodium taurocholate cotransporting polypeptide and bile salt export pump and downregulation of cholesterol 7α-hydroxylase in the liver of patients with end-stage primary biliary cirrhosis.

Authors:  Yasuaki Takeyama; Kazuko Kanegae; Shinjiro Inomata; Kazuhide Takata; Takashi Tanaka; Shu-Ichi Ueda; Keiji Yokoyama; Daisuke Morihara; Shinya Nishizawa; Akira Anan; Makoto Irie; Kaoru Iwata; Satoshi Shakado; Tetsuro Sohda; Shotaro Sakisaka
Journal:  Med Mol Morphol       Date:  2010-09-21       Impact factor: 2.309

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.